RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 22:39:26时区推断·⟳ 抓取 22:45:23·⚡ 决策 07-31 22:54:13 +8m50s·87.7 天前
Karyopharm子宫内膜癌3期试验未达PFS主要终点，股价盘中暴跌
Karyopharm Therapeutics（KPTI.US）官方确认XPORT-EC-042子宫内膜癌3期试验未达PFS主要终点，并称将减少该适应症投入，直接削弱selinexor适应症扩张期权。
📄 原文RTTNews Biotech↗ 原文
Karyopharm's Phase 3 Endometrial Cancer Trial Misses Endpoint; Stock Slides
Karyopharm Therapeutics Inc. (KPTI), announced yesterday topline results from its Phase 3 XPORT-EC-042 trial evaluating…
不做 Karyopharm Therapeutics（KPTI.US）
直接利空成立，但到达时已盘中暴跌约65.7%，剩余做空edge主要已释放；且stock_quote两次504未返回ok，按契约不能生成可回测SHORT，保留风险信号但不新开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司正式披露XPORT-EC-042未达PFS主要终点，同时表示将减少子宫内膜癌项目计划投入。
- RTTNews在美股盘中转述试验失败并报道KPTI约2.40美元、下跌65.71%。市场反应:KPTI.US盘中约2.40美元，跌65.71%。
关键理由
- Karyopharm Therapeutics（KPTI.US）官方确认XPORT-EC-042子宫内膜癌3期试验未达PFS主要终点，并称将减少该适应症投入，直接削弱selinexor适应症扩张期权。
- 该项目尚未贡献现有收入；公司2025年总收入约1.46亿美元、2026年总收入指引1.30亿-1.50亿美元主要来自XPOVIO现有多发性骨髓瘤业务，因此本次损害更偏管线估值而非当期收入。
- 信号到达时RTTNews称KPTI盘中约2.40美元、跌65.71%，核心负面已在开盘后快速重定价，剩余做空收益/挤压风险不对称。
主要风险
- 做空侧最大风险是其他管线仍在推进：公司称骨髓纤维化、多发性骨髓瘤试验不受本次结果影响，并预计下半年仍有sNDA、指南和SENTRY-2数据节点。
- 行情MCP连续504未返回stock_quote ok，无法按系统契约生成可回测ENTER空单；本文仅保留风险信号供已有多头风控。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
公司同一新闻稿称XPORT-EC-042结果不影响selinexor其他潜在适应症试验，仍关注骨髓纤维化和多发性骨髓瘤节点。
检索:Karyopharm myelofibrosis multiple myeloma ongoing programs unaffected 2026 revenue guidance 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-05-14 · 影响 weakens
公司一季度仍重申2026年总收入1.30亿-1.50亿美元、美国XPOVIO净产品收入1.15亿-1.30亿美元，说明本次失败不是现有收入直接归零。
检索:Karyopharm 2026 revenue guidance XPOVIO net product revenue 原文 ↗ - 做空前查反向 · 来源 kb_search · 影响 none
内部KB检索实际调用但服务504，未能补充内部反证或旧闻证据。
检索:Karyopharm selinexor XPORT-EC-042 missed primary endpoint endometrial cancer
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,035 字
Karyopharm Therapeutics Inc. (KPTI), announced yesterday topline results from its Phase 3 XPORT-EC-042 trial evaluating Selinexor as a maintenance-only therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer.
The study did not meet its primary endpoint of progression free survival, though a favorable trend was observed in the Selinexor arm.
Endometrial cancer is the most common gynecologic malignancy in the U.S. with approximately 68,000 cases projected in 2026. Patients with TP53 wild-type and mismatch repair—proficient tumors continue to face limited treatment options. In the modified intent-to-treat population of 236 patients, median PFS was 12.75 months with Selinexor compared to 7.43 months with placebo, representing a 5.3-month improvement. While the difference did not reach statistical significance, investigators noted the outcome highlights the potential of XPO1 inhibition in this patient group.
The safety and tolerability profile of Selinexor was consistent with prior studies, with no new safety signals reported. Karyopharm plans to continue following patients for longer-term outcomes and will present full data at an upcoming medical meeting.
Upcoming milestones:
-Submission of a supplemental NDA for Selinexor in myelofibrosis in the second half of 2026.
-Potential addition of Selinexor to relevant compendia guidelines in the second half of 2026.
-Topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial in patients with myelofibrosis the second half of 2026.
KPTI has traded between $2.09 and $10.99 over the past year. The stock is currently trading at $2.40, down 65.71%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
The study did not meet its primary endpoint of progression free survival, though a favorable trend was observed in the Selinexor arm.
Endometrial cancer is the most common gynecologic malignancy in the U.S. with approximately 68,000 cases projected in 2026. Patients with TP53 wild-type and mismatch repair—proficient tumors continue to face limited treatment options. In the modified intent-to-treat population of 236 patients, median PFS was 12.75 months with Selinexor compared to 7.43 months with placebo, representing a 5.3-month improvement. While the difference did not reach statistical significance, investigators noted the outcome highlights the potential of XPO1 inhibition in this patient group.
The safety and tolerability profile of Selinexor was consistent with prior studies, with no new safety signals reported. Karyopharm plans to continue following patients for longer-term outcomes and will present full data at an upcoming medical meeting.
Upcoming milestones:
-Submission of a supplemental NDA for Selinexor in myelofibrosis in the second half of 2026.
-Potential addition of Selinexor to relevant compendia guidelines in the second half of 2026.
-Topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial in patients with myelofibrosis the second half of 2026.
KPTI has traded between $2.09 and $10.99 over the past year. The stock is currently trading at $2.40, down 65.71%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。